close icon

AMD Stock Carries More Risk than Reward near $25

AMD stock is up almost 34% since the start of 2019, beating the year-to-date return of the S&P 500 three times over. Shares fell to $16.04 on December 26th, when the bulls finally managed to fight back. Yesterday, the stock closed at $24.71, following an intraday high of $25.51.

Most people, anticipating the rally to continue, would often buy a stock after it has risen substantially. But as Warren Buffett once put it, “the investor of today does not profit from yesterday’s growth.” So let’s take a look at AMD through an Elliott Wave perspective and see if it is still a good stock to pick up for 2019.

Elliott Wave analysis of AMD stock suggests it is vulnerable

The 2-hour chart shows that the sharp selloff from $34.14 to $16.17 can actually be seen as a textbook five-wave impulse in wave (A), whose wave 5 is extended.

According to the Elliott Wave theory, a three-wave correction in the opposite direction follows every impulse pattern. And indeed, the rest of the chart reveals an A-B-C expanding flat correction in wave (B) up to $25.51 so far.

If this count is correct, there is a complete 5-3 cycle to the south from the September 2018 top at $34.14. Unfortunately for AMD shareholders, this means another decline to under $16 a share can be expected in wave (C) down from now on.

The MACD indicator further supports the negative outlook. It shows a bearish divergence between waves iii and v of C of (B), highlighting the bulls’ hidden vulnerability near the 50% Fibonacci level. In our opinion, this is definitely not the time to join the bulls in AMD stock.

Did you like this analysis? Our Elliott Wave Video Course can teach you how to uncover the patterns yourself!



Stay informed with our newsletter

Latest Elliott Wave analysis on different topics delivered to you weekly.

Privacy policy
You may also like:

Shopify is One of Many Bubble Stocks Out There

It is becoming pretty clear that a speculative bubble is inflating right now. Money-losing companies with market caps in the tens and even hundreds of billions of dollars have become the norm, not the exception. People, who have been in the market for just a couple of months are bragging online about the phenomenal returns…

Read More »

Undervalued Bristol Myers Stock Can Still Get Cheaper

It’s been almost two years since we shared our bullish stance on Bristol Myers stock. Shares in the pharmaceutical major were changing hands for less than $46 in April, 2019. The company had just announced its planned acquisition of Celgene for about $74 billion and Wall Street apparently didn’t like the risks involved. However, the…

Read More »

DraftKings on the Verge of Another 40% Decline

It’s been almost three and a half months since we examined DraftKings stock in October, 2020. The share price was hovering near $57 after a strong run from $10.60 to over $64 in just several months. The regulatory environment in the U.S. seemed to be warming up and many analysts hurried to issue their BUY…

Read More »

AMN Healthcare Stock to Suffer a 2020-Like Drop

AMN Healthcare Services provides workforce and staffing solutions to healthcare facilities in the U.S. The company is relatively small with a market capitalization of less than $4 billion. However, small companies can make for excellent returns if one happens to identify the winners. And indeed, between late-2011 and early-2020, AMN stock from under $4 to…

Read More »

Zoetis Stock Getting Ahead of Itself, Invites Correction

Based in Parsippany, NJ, Zoetis Inc. is an animal medicine and vaccine developer and manufacturer. The company went public in 2013 and has been enjoying steady growth since. With the stock currently above $160 a share, Zoetis holds a market cap of nearly $80 billion. For a profitable and growing company like Zoetis, a rising…

Read More »

CBOE Stock Looking Good After a Record Year

CBOE Global Markets Inc. is an equities, options and futures exchange operator in the U.S. and Europe. The company traces its roots back to Chicago in 1973, when it practically invented options trading in its present form. CBOE is literally part of the very infrastructure of modern financial markets. So it is not surprising that…

Read More »

Novo Nordisk Bulls Have an Elliott Wave Problem

Novo Nordisk A/S is a Danish pharmaceuticals major with a market cap of over $160 billion. People need their medication even in recessions, so the company’s business wasn’t as affected by the 2020 crisis as most other industries. Novo Nordisk remains a top-notch pharma with consistent profits and revenue and no debt whatsoever. And the…

Read More »

More analyses